Neuprex rBPI-21 bactericidal and endotoxin neutralizing agent: Began a Phase II trial in 72 patients in the Netherlands, with the primary endpoint of reducing c

XOMA Corp. (XOMA), Berkeley, Calif. Product: Neuprex rBPI-21 bactericidal and endotoxin neutralizing agent Indication: Surgical removal of part of the liver (partial hepatectomy) Status: Began a Phase...